Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656639 | 0.91 | CYP19A1 (0.44) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL19670976 | 0.84 | TAAR1 (0.50) | CYP11B1CYP11B2KIF11 | |
| SCHEMBL18427184 | 0.83 | CYP19A1 (0.49) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL25054046 | 0.81 | CYP19A1 (0.47) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL22217252 | 0.81 | CYP19A1 (0.40) | CYP19A1KIF11 | |
| SCHEMBL21362659 | 0.80 | CYP19A1 (0.41) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL21419437 | 0.80 | CYP19A1 (0.38) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL19788273 | 0.80 | CNR1 (0.55) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL23312229 | 0.80 | CYP19A1 (0.42) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 | |
| SCHEMBL21553999 | 0.80 | CYP19A1 (0.42) | CYP19A1LMNACYP1A2CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BGI SHENZHEN (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CYP19A1 648/4885LMNA 1869/4885CYP1A2 3575/4885 |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOS1, NQO1, NOS2 | CYP19A1 127/4885LMNA 3149/4885CYP1A2 193/4885 |
| US-20240067673-A1 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | NT5C3B, NT5E, NT5C2 | CYP19A1 4215/4885LMNA 559/4885CYP1A2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.